AI Image
FDA warns GLP-1 drugs carry potential risk of rare eye condition
STAT • • business
Key Points:
- The FDA has issued a warning that GLP-1 drugs may pose a risk for a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden vision loss and potentially blindness.
- NAION, sometimes described as an "eye stroke," results from insufficient blood flow to the optic nerve and currently has no proven treatments.
- Popular GLP-1 drugs like Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lilly’s Mounjaro and Zepbound, have surged in use due to their strong weight loss effects.
- The FDA is requiring pharmaceutical companies to inform patients and healthcare providers about this potential risk, highlighting that side effects may emerge in widespread use beyond clinical trials.
